Figures & data
Figure 1. Study population selection.
Table 1. Characteristics of adults 19–64 years of age newly diagnosed with chronic or immunocompromising conditions in 2009–2013 in the US.
Figure 2. Pneumococcal vaccination rates among adults 19–64 years of age newly diagnosed with chronic or immunocompromising conditions, by condition and years of follow-up available.
Table 2. Pneumococcal vaccination rates among adults 19–64 years of age newly diagnosed with chronic or immunocompromising conditions, by condition and years of follow-up data available.
Table 3. Gompertz Accelerated failure time model results on factors associated with pneumococcal vaccination in adults 19–64 years of age newly diagnosed with chronic or immunocompromising conditions.
Table A1. International Classification of Diseases, Current Procedural Terminology, and National Drug Codes used to identify qualifying medical conditions and relevant vaccinations.
Table A2. Time from initial diagnosis to pneumococcal vaccination in adults 19–64 years of age newly diagnosed with chronic or immunocompromising conditions.
Table A3. Proportions of pneumococcal vaccination by condition: comparison of adults with Medicaid and commercial health plansA.